Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C (MANFOL)

Clinical Trial ID NCT00671996

Rank	Title	Journal	Year	PubWeight™‹?›
1	Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.	J Natl Cancer Inst	2006	2.18
2	Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium.	Acta Radiol	2001	1.55
3	Redox modulation of chemotherapy-induced tumor cell killing and normal tissue toxicity.	J Natl Cancer Inst	2006	0.94
4	Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries.	J Pharmacol Exp Ther	1994	0.83
5	Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties?	Biochem Biophys Res Commun	1999	0.81
6	The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity.	Cancer Res	2006	0.81
7	First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study.	Transl Oncol	2012	0.79